deltatrials
Terminated PHASE2 INTERVENTIONAL NCT00020969

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes

Sponsor: CTI BioPharma

Conditions Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms
Interventions arsenic trioxide
Updated 6 times since 2017 Last updated: Oct 2, 2020 Started: Mar 31, 2001 Primary completion: Jan 31, 2005 Completion: Jan 31, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from CTI BioPharma

See all terminations from CTI BioPharma

Other Leukemia trials with similar outcome

Browse all Leukemia trials

Listed as NCT00020969, this PHASE2 trial focuses on Leukemia and Myelodysplastic Syndromes and remains terminated or withdrawn. Sponsored by CTI BioPharma, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotUnknown Status~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

  5. Jun 2018 — Nov 2020 [monthly]

    Unknown Status PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CTI BioPharma
  • National Cancer Institute (NCI)
Data source: CTI BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations